Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Incidence patterns of Acute Myeloid Leukemia in the United States from 1999 to 2021: Analysis by age, sex, and race/ethnicity

Fatima Ali, Ibrahim Hassan, Amna Khalid Nov 03, 2025 pp. 6899-6899 10.1182/blood-2025-6899

Abstract Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with variable incidence by age...

NQO1 modulates CD38 surface expression in multiple myeloma

Seungbin Han, Christina Verbruggen, Silvia Nerreter et al. Nov 03, 2025 pp. 5718-5718 10.1182/blood-2025-5718

Abstract Introduction: The efficacy of immunotherapies such as monoclonal antibodies (mAbs), CAR T cells, and bispecific...

Poor nutritional intake prior to allogeneic hematopoietic cell transplantation is associated with higher incidence of lower-gastrointestinal graft-versus-host disease

Natalie Smith, Antonio Luiz Cruz Gomes, Sally Mokhtari et al. Nov 03, 2025 pp. 4250-4250 10.1182/blood-2025-4250

Abstract Introduction. Nutritional intake during allogeneic hematopoietic cell transplantation (allo-HCT) may influence clinical outcomes an...

Stability of ADAMTS13 activity in liquid plasma and its clinical application in therapeutic plasma exchange for thrombotic thrombocytopenic purpura

Wenjing Cao, John Weiss, John Sheehan et al. Nov 03, 2025 pp. 4922-4922 10.1182/blood-2025-4922

Abstract Background Liquid plasma (LP) is a never-frozen product stored at 1-6 °C with a shelf-life of 21–26 days and is often used as a bri...

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Jian Huang, Bingbing Wen, Tiejun Gong et al. Nov 03, 2025 pp. 7351-7351 10.1182/blood-2025-7351

Abstract Introduction:JAK inhibitors (JAKi) are crucial in managing polycythaemia vera (PV) by improving symptoms and reducing spleen volume...

Social determinants of health and emergency department utilization in sickle cell disease: A systematic review and meta-analysis

Mohit Mirchandani, Chandan Das, Inae Park et al. Nov 03, 2025 pp. 7985-7985 10.1182/blood-2025-7985

Abstract Introduction Social determinants of health (SDoH), such as economic hardship, housing insecurity, and healthcare access, drive outc...

Reduction of iron overload in hereditary hemochromatosis model mice by presence of iron metabolism mutant

Staton McBroom, Amber Wiggins, Nidhi Rao et al. Nov 03, 2025 pp. 4687-4687 10.1182/blood-2025-4687

Abstract Hereditary Hemochromatosis (HH) is an iron overloading disease for which repeated phlebotomy, followed by maintenance phlebotomy, a...

Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown et al. Nov 03, 2025 pp. 5259-5259 10.1182/blood-2025-5259

Abstract INTRODUCTION: Mutations in the Enhancer of Zeste Homolog 2(EZH2) occur in ~ 4% of Acute Myelogenous Leukemia (AML) cases, and confe...

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Nirav Shah, Scott Huntington, David Lewis et al. Nov 03, 2025 pp. 5359-5359 10.1182/blood-2025-5359

Abstract Introduction: The B-cell receptor signaling pathway mediated by BTK is a validated therapeutic target in Waldenström macroglobuline...

Hyperfractionated cyclophosphamide, bortezomib and dexamethasone for initial treatment of newly diagnosed multiple myeloma with renal dysfunction

Guneet Kaleka, Paul Kaesberg, Brian Jonas et al. Nov 03, 2025 pp. 4057-4057 10.1182/blood-2025-4057

Abstract Introduction: Renal injury due to light chain cast nephropathy is a defining feature of multiple myeloma. A prospective study previo...

Real-world descriptive analysis of the use of bispecific t cell engagers (BiTEs) in the treatment of hematological malignancies in Qatar: A state-wide retrospective cohort study

Rawan Dawoud, Farah Jibril, Maria Benkhadra et al. Nov 03, 2025 pp. 7264-7264 10.1182/blood-2025-7264

Abstract Introduction One of the most promising modalities in immunotherapy includes Bispecific T cell Engagers (BiTEs),...

Hyperuricemia modifies multiple myeloma pathobiology and modulates conventional, novel, and immuno-oncology drug sensitivity

Upasana Ray, Isere Kuiatse, Robert Orlowski Nov 03, 2025 pp. 5734-5734 10.1182/blood-2025-5734

Abstract Background: Renal impairment is seen in up to 50% or more of patients with multiple myeloma and has been linked to inferior short-...

Integrated clinico-biological profiling identifies a high-risk epigenetic signature in Mantle Cell Lymphoma: A lysa study

Morgane Cheminant, Sophie Kaltenbach, Bruno Tesson et al. Nov 03, 2025 pp. 661-661 10.1182/blood-2025-661

Abstract Introduction: Immunochemotherapy remains the cornerstone of treatment for Mantle Cell Lymphoma (MCL). However,...

Mortality trends of sepsis in patients with leukemia in the United States (1999–2020): A CDC wonder database analysis

Hafsa Shahid, Anisha Manzoor, Sania Batool et al. Nov 03, 2025 pp. 4603-4603 10.1182/blood-2025-4603

Abstract Background: Patients with leukemia are more likely to develop sepsis as a result of disease-related immunosuppression and cytotoxic...

Clonal evolution of pediatric Acute Myeloid Leukemia

Masayuki Umeda, Pandurang Kolekar, Anna Huskey et al. Nov 03, 2025 pp. 1721-1721 10.1182/blood-2025-1721

Abstract Relapse remains the major cause of mortality in pediatric acute myeloid leukemia (AML). Although initiating driver alterations are...

Whole genome sequencing uncovers novel BCR::ABL1 breakpoints and variants in leukemia: Implications for personalized medicine

Robert Huether, Derick Hoskinson, Raul Torres et al. Nov 03, 2025 pp. 6130-6130 10.1182/blood-2025-6130

Abstract Background: The BCR::ABL1 fusion gene is a hallmark of chronic myeloid leukemia (CML) and is also present in a subset of acute lymp...

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Manali Kamdar, Scott Solomon, Jon Arnason et al. Nov 03, 2025 pp. 3710-3710 10.1182/blood-2025-3710

Abstract Introduction: Liso-cel is an autologous, CD19-directed, 4-1BB CAR T cell product. TRANSFORM (NCT03575351) is a global, randomized, o...

JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells.

Jeremy Deuel, Andrejs Makarovs, Sheidasadat Goosheh et al. Nov 03, 2025 pp. 3149-3149 10.1182/blood-2025-3149

Abstract Retrotransposon expression must be tightly controlled, particularly in long-lived multipotent stem cells, to prevent deleterious co...

Survival and gvhd disparities in UAE patients undergoing allo-HSCT abroad: A multicenter benchmark study

Naveed Syed, Mohamed Abu Haleeqa, Fatema Al Kaabi et al. Nov 03, 2025 pp. 7791-7791 10.1182/blood-2025-7791

Abstract Background: Until 2022, the United Arab Emirates (UAE) lacked in-country allogenic hematopoietic stem cell transplant (allo-HSCT) s...

Outcomes of plasmapheresis in patients with HLH: A nationwide analysis from 2016–2022

Adnan Humam Hajjar, Abdulmalek Aljafari, Shehab Mohamed et al. Nov 03, 2025 pp. 2992-2992 10.1182/blood-2025-2992

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening hyperinflammatory syndrome characterized by unc...

Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group

Julia Stomper, Michal Kicinski, Tobias Ma et al. Nov 03, 2025 pp. 1709-1709 10.1182/blood-2025-1709

Abstract Introduction DNA-hypomethylating agents (HMA) have become standard treatment for patients (pts) with acute myel...

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Sikander Ailawadhi, Divaya Bhutani, Antje Hoering et al. Nov 03, 2025 pp. 1840-1840 10.1182/blood-2025-1840

Abstract Background and Significance: Waldenström's Macroglobulinemia (WM) is an indolent B cell disorder characterized by proliferation of...

Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up

Elias Jabbour, Federico Lussana, Pilar Martinez Sanchez et al. Nov 03, 2025 pp. 5117-5117 10.1182/blood-2025-5117

Abstract Introduction: Blinatumomab, a BiTE® (bispecific T-cell engager) molecule, is an effective treatment for relapsed or refractory (R/R...

Increased prevalence of anemia among recently immigrated female South Asian college students: A cross-sectional study from three primary care clinics in a college town

Amruth Alluri, Jason Truong, Yashaswi Guntupalli Nov 03, 2025 pp. 6258-6258 10.1182/blood-2025-6258

Abstract Background: Anemia is a major health concern among women of reproductive age, particularly in South Asia, where nutritional deficie...

Volume and nature of classical hematology outpatient consults within a national cancer institute-designated comprehensive cancer center

Emily Wolf, Michelle Neitzke, Jithma Abeykoon et al. Nov 03, 2025 pp. 8208-8208 10.1182/blood-2025-8208

Abstract Introduction A 2017 survey by the American Society of Hematology found a widespread perceived shortage of classical hematologists i...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page